Effect of adjuvant therapy on development of diabetes in mouse and man

The Lancet

Volumn 343, Issue 8899, 1994, Pages 706-707

  Shehadeh, N ^a   Bruchlim, I ^a   Vardi, P ^a   Calcinaro, F ^b   Lafferty, Kj ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BCG VACCINE; CYCLOPHOSPHAMIDE; FREUND ADJUVANT; INSULIN;

ADJUVANT THERAPY; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0028331371     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)91583-0     Document Type: Article

References (6)

1. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice
2. Prevention of recurrence of insulin-dependent diabetes mellitus in islet cell-transplanted diabetic NOD mice using adjuvant therapy
3. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in non-obese diabetic mice
4. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes
5. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy
6. Single administration of bacillus Calmette-Guerin (BCG) vaccine in nonobese diabetic (NOD) mice results in suppression of in vitro T-lymphocyte proliferation and regression of insulitis